Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 95%
filed 2026-07-06
Item 2.01
CoreCivic completed the sale of two detention facilities (California City Detention Facility and Otay Mesa Detention Center) to the U.S. Department of Homeland Security for an aggregate gross sales price of $1.5 billion on July 2, 2026, with net proceeds of approximately $1.1 billion after taxes and transaction expenses. The company intends to use proceeds to repay debt and pursue growth opportunities. This is a material disposition of significant assets representing a substantial portion of the company's real estate portfolio.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 1.01
Corbus Pharmaceuticals appointed Leonardo Viana Nicacio, M.D. as Chief Medical Officer, effective August 3, 2026, under a two-year employment agreement. Dr. Nicacio brings 20+ years of pharmaceutical development experience, including pivotal work on TIVDAK®, and expertise in ADCs and HPV-driven oncology directly aligned with the company's strategic priorities as it approaches initiation of the TEMPO-1 registrational study. The appointment includes material inducement equity awards of $2.1 million.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-06
Item 2.01
Middleby completed a spin-off of its Food Processing business as Midera Food Processing, Inc. on July 6, 2026, distributing 100% of Midera common stock to shareholders on a pro rata basis. Midera began trading on Nasdaq under ticker 'MFP' on July 7, 2026, representing a material change of control and disposition of a significant business segment.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-06
Item 5.02
Three executives departed from Middleby effective upon completion of the Midera spin-off: directors Robert A. Nerbonne and Cathy T. McCarthy resigned from the Board to join Midera's board, and Matthew R. Fuchsen resigned as Chief Development Officer to become Midera's Chief Strategy Officer.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-06
Item 1.01
Midera Food Processing completed its spin-off from The Middleby Corporation on July 6, 2026, with 100% of Midera's outstanding shares distributed pro rata to Middleby stockholders. Midera commenced independent public trading on Nasdaq under ticker 'MFP' on July 7, 2026, governed by multiple definitive agreements including a Separation and Distribution Agreement, Tax Matters Agreement, Employee Matters Agreement, Intellectual Property Matters Agreement, and Transition Services Agreement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Effective immediately prior to the spin-off consummation, Midera appointed a complete board of directors (8 members) and executive leadership team, including Mark M. Salman as CEO, Amy A. Campbell as CFO, Mark S. Bowie as COO, and Matthew R. Fuchsen as Chief Strategy Officer.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-06
EX-99.1
MindWalk announced its inclusion in the Russell 3000E Index effective June 26, 2026, as part of FTSE Russell's semi-annual reconstitution. While index inclusion is primarily a market-visibility and operational milestone rather than a discrete financial or governance event, it is material because it expands institutional investment eligibility and access to approximately $12.2 trillion in benchmarked assets, directly affecting the company's capital-market positioning and liquidity profile. This is an operational/strategic milestone that would affect a reasonable investor's assessment of the registrant's market accessibility.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-07-06
EX-99.1
Rogers Communications has signed an agreement to acquire the remaining 25% ownership stake in Maple Leaf Sports & Entertainment (MLSE) from Kilmer Sports Inc. for C$4.35 billion, increasing Rogers' ownership to 100%. This is a material acquisition transaction that would significantly affect investor assessment of the registrant's capital allocation, strategic direction, and financial position. The transaction is subject to league approvals and expected to close in Q4 2026.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-06
Item 8.01
The board of trustees declared a dividend of $0.625 per common share payable on August 14, 2026, to shareholders of record as of June 30, 2026. The disclosure explicitly states the dividend amount, payment date, and record date, with options for reinvestment or cash payment. This is a routine but material dividend distribution to shareholders.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-06
EX-99.1
This news release announces the closing of an acquisition by Cameco and Orano of TEPCO Resources Inc.'s 5% participating interest in the Cigar Lake Joint Venture. The transaction materially increases Cameco's ownership stake in the Cigar Lake uranium mine from approximately 54.5% to 57.418%, a significant increase in a material asset. This is a completed material acquisition that would affect a reasonable investor's assessment of Cameco's asset base and operational control.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 75%
filed 2026-07-06
The 6-K furnishes an "Amended and Restated Credit Agreement, dated as of June 24, 2026" as Exhibit 99.1. An amendment and restatement of a credit facility constitutes a material modification to the registrant's direct financial obligations. While the exhibit itself is not provided in the body text, the disclosure of a restated credit agreement is a debt-related event that would affect a reasonable investor's assessment of the registrant's capital structure and financing arrangements.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-06
Item 8.01
The filing discloses the declaration of June 2026 dividends for the Fund's common shares, with Class I shares receiving $0.1887 per share (9.00% annualized distribution yield), payable on or about July 24, 2026. This is a routine but material dividend distribution disclosure typical of closed-end funds, filed under Item 8.01 (Other Events).
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-06
Item 7.01
The board of directors declared a distribution of $0.42 per share payable to shareholders of record, with cash payment or reinvestment options available. This is a clear dividend or distribution declaration to shareholders, which is a material event affecting investor returns and capital allocation decisions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 8.01
Ouster completed a registered public offering of 3,621,876 shares of common stock at $55.22 per share, raising approximately $191.9 million in net proceeds. This is a material equity issuance disclosed under Item 8.01 that dilutes existing shareholders and represents a significant capital-raising event for the company.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 99%
filed 2026-07-06
Item 2.03
Extra Space Storage LP completed an underwritten public offering of $550 million in 4.900% Senior Notes due 2032, creating a material direct financial obligation with specified terms and restrictive covenants.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-06
Item 5.07
Achieve Life Sciences held an Annual Meeting of security holders at which stockholders voted on four matters: election of nine directors, ratification of PricewaterhouseCoopers LLP as independent auditor, a non-binding advisory vote on named executive officer compensation, and approval of a Certificate of Amendment to increase authorized common shares from 150 million to 300 million. All matters were approved with certified vote tallies disclosed.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 80%
filed 2026-07-06
Item 1.01
AGENUS extended the maturity of $5.09 million in senior subordinated notes from June 20, 2026 to February 18, 2027, and issued warrants to purchase 221,525 shares of common stock as part of a material restructuring of its financial obligations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-06
Item 3.02
AGENUS issued unregistered warrants to purchase 221,525 shares of common stock, representing a dilutive equity issuance to existing shareholders.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-06
The 6-K discloses completion of a redomiciliation and reorganization whereby Marex Group Limited (Bermuda) became the parent holding company of Marex Group plc (UK) through a statutory scheme of arrangement approved by shareholders on May 21, 2026 and the High Court on June 26, 2026, effective July 1, 2026. This constitutes a material change of control and corporate restructuring. The filing also documents New Marex's assumption of all outstanding debt obligations ($1.6 billion in senior notes, subordinated notes, and contingent capital securities) as successor issuer, which is integral to the reorganization transaction.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-06
Item 7.01
The filing discloses an announcement of the Company's second quarter 2026 financial results to be released on August 6, 2026, with a conference call scheduled for August 7, 2026. The press release explicitly states "Morgan Stanley Direct Lending Fund Announces Second Quarter 2026 Earnings Release and Conference Call," which is a standard earnings announcement. This is material to investors as it provides notice of when quarterly financial results will be disclosed.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-06
Item 5.02
The filing discloses both a director resignation (Dr. Jovan-Embiricos) and the election of a new director (Laurie Keating to the Board and Audit Committee, effective August 1, 2026). While both events occur, the principal action emphasized in the disclosure is the appointment of Ms. Keating, including detailed compensation terms (18,000 option grant, $40,000 annual cash, $7,500 Audit Committee fee). Director appointments are material governance events affecting board composition and oversight.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-06
Item 1.01
Fortress Net Lease REIT entered into a New Lender Joinder Agreement that increases the aggregate principal amount of its Credit Facilities from $1,800,000,000 to $1,900,000,000, including increases to both the Revolving Credit Facility (from $1,475,000,000 to $1,545,000,000) and the Term Loan Facility (from $325,000,000 to $355,000,000).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
Warburg Pincus Access Fund sold unregistered limited partnership units totaling $11.1 million to third-party investors on June 1, 2026, pursuant to Section 4(a)(2) and Regulation D exemptions, representing a significant capital raise and expansion of the Fund's investor base.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-06
Item 2.02
RxSight issued a press release on July 6, 2026 announcing preliminary unaudited second quarter 2026 financial results, including total company revenue of approximately $32–$34 million, LAL unit sales of 24,917 units, and cash position of approximately $209 million. The filing is disclosed under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes updated 2026 full-year guidance ($140–$160 million revenue) and gross margin expectations, making it a material financial results announcement.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-06
Item 1.01
RxSight entered into a material License, Collaboration and Development Agreement with Alcon on June 30, 2026, granting Alcon a non-exclusive, worldwide, royalty-bearing license to develop and commercialize light-adjustable versions of Alcon's simultaneous vision intraocular lenses using RxSight's LAL technology. The agreement provides RxSight with a $60 million upfront payment, up to $140 million in additional milestone payments, and 30% royalties on net sales, constituting a significant strategic collaboration that materially affects RxSight's revenue prospects and market position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
The filing discloses an unregistered sale of 1,873,541.8118 common shares for $47.3 million in aggregate consideration under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive equity issuance by a REIT in a continuous private offering, exempt from registration. The magnitude ($47.3M) and share count are material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-06
Item 8.01
The disclosure describes the entry into an underwriting agreement for a $500 million public offering of 4.950% Senior Notes due 2032, fully guaranteed by the Company and its subsidiaries. This is a material creation of a direct financial obligation under Item 8.01 (Other Events), with proceeds intended for general corporate purposes and potential debt repayment. The size, terms, and guaranteed structure make this a clear debt issuance event.
View raw filing on EDGAR →
8-K
Governance Other
confidence 65%
filed 2026-07-06
Item 5.03
Dell Technologies amended its bylaws to elect governance under Texas Business Organizations Code Section 21.373, which imposes heightened shareholder proposal thresholds including a minimum $1M market value or 3% ownership requirement, a six-month holding period, and a 67% solicitation requirement. This material modification to security holder rights affects investor assessment of voting power and shareholder proposal mechanisms.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-06
EX-99.1
Wallbox received a NYSE notice on February 12, 2026 for non-compliance with Section 802.01B regarding average global market capitalization and stockholders' equity. The NYSE has now accepted the Company's compliance plan, granting an 18-month cure period to achieve either $50 million in stockholders' equity or $50 million average market capitalization. This is a material delisting-risk disclosure: the Company faces potential suspension or delisting if it fails to meet the plan milestones, and the announcement explicitly addresses the NYSE's continued listing standards and the conditional nature of ongoing listing.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-06
Item 5.02
Jesse Coury resigned as Chief Financial Officer of Greystone Housing Impact Investors LP, the principal disclosed action. While the filing also describes a post-departure contractor agreement at $300/hour through September 30, 2026, the core event is the CFO's departure. The departure of a named executive officer in a financial leadership role is material to investors assessing management continuity and operational risk.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-07-06
Item 1.01
Targa Resources entered into a Seventeenth Amendment to its Receivables Purchase Agreement on July 1, 2026, extending the Facility Termination Date to July 30, 2027 and establishing a new uncommitted $200 million line. With approximately $451 million in outstanding trade receivable purchases, this amendment materially modifies the company's financing structure and credit facility. While this is technically an amendment to an existing securitization facility rather than a new debt issuance, it creates new financial obligations and extends the company's access to capital, which falls within the debt_issuance category as it represents a material creation or amendment of a direct financial obligation.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 90%
filed 2026-07-06
Item 1.01
Landstar entered into a Third Amended and Restated Credit Agreement on June 30, 2026, establishing a $300 million revolving credit facility with an additional $500 million accordion feature and a five-year termination date (June 30, 2031). This represents a material amendment to the company's direct financial obligations and replaces the prior credit agreement.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-06
Item 3.03
American Bitcoin Corp. effected a 1-for-15 reverse stock split of its Class A and Class B common stock on July 2, 2026, reducing outstanding shares from approximately 1.09 billion to 73 million. The reverse split was approved by stockholders on June 22, 2026, and was undertaken to maintain compliance with Nasdaq's minimum bid price listing requirement.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-07-06
Item 2.03
Nuvation Bio completed a registered public offering of $287.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, including the full exercise of a $37.5 million greenshoe over-allotment option on July 6, 2026, generating net proceeds of approximately $277.6 million after underwriting costs.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 70%
filed 2026-07-06
Item 1.01
Vroom entered into Amendment No. 29 to its warehouse credit facility, which materially restructures the terms by modifying financial covenants (leverage ratio, tangible net worth, advance rate), extending the commitment termination date from July 2, 2026 to June 2, 2027, and adding a new performance guaranty from VFH.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-06
Item 1.01
Vertex Pharmaceuticals entered into a definitive merger agreement on July 6, 2026, to acquire Crinetics Pharmaceuticals for $85 per share in cash, representing a $10 billion total transaction ($8.8 billion net of cash). The acquisition is expected to be transformative, adding endocrinology assets including PALSONIFY and atumelnant to Vertex's pipeline, with $5 billion+ peak sales opportunity and accretion to non-GAAP operating income by 2029.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-06
Item 5.02
The filing discloses two executive changes: Tamar Howson's resignation from the Board and Compensation Committee on June 29, 2026, and Erik Lundgren's appointment as a Class II director on July 5, 2026. While both events are disclosed, the principal action emphasized is Lundgren's appointment to the Board following the Nominating and Corporate Governance Committee's recommendation. The appointment of the CEO to the Board is the forward-looking material event, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-06
Item 1.01
On July 2, 2026, the Company entered into a Sixth Amended and Restated Credit Agreement establishing a $1.2 billion unsecured revolving credit facility maturing in 2031, representing a material refinancing and extension of its existing revolving credit agreement.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-07-06
EX-99.1
REE Automotive received a delisting notice from Nasdaq on June 30, 2026, determining that the Company's Class A ordinary shares will be delisted from the Nasdaq Capital Market effective July 7, 2026, due to failure to regain compliance with the Minimum Bid Price Requirement (closing bid price below $1.00 per share for 30 consecutive business days). The Company exhausted its 180-day cure periods and does not intend to request a hearing. This is a terminal delisting determination, not merely a warning or deficiency notice.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-06
Item 5.02
The filing discloses multiple executive appointments effective July 1, 2026: Charles Nelson as Chairman and CEO (promoted from President and COO), Ted Warner as President and director (promoted from CFO), and José Rodriguez as Chief Operating Officer (promoted from VP). While the section also includes an executive departure (E. Will Gray II's resignation as director and demotion from CEO to President, Permian), the principal disclosed actions center on the appointments and promotions of three executives to senior leadership roles, with corresponding employment agreement amendments and compensatory arrangements. These leadership changes are material to investors assessing the registrant's governance and strategic direction.
View raw filing on EDGAR →
6-K
Legal Other
confidence 85%
filed 2026-07-06
EX-99.1
This press release discloses a law enforcement action by the FBI involving seizure of domains associated with NetNut (Alarum's subsidiary), resulting in service disruptions that the Company acknowledges are "likely to have a material adverse effect on the Company's operations, financial results and its ability to provide certain services to customers." While the disclosure involves potential regulatory/law enforcement investigation rather than a formal litigation filing or settlement, it is a material legal/regulatory event that does not fit the specific categories of material_litigation (no lawsuit filed), cybersecurity_incident (no breach disclosed), or covenant_breach (no debt default). The domain seizures and ongoing investigation constitute a significant legal/regulatory matter warranting disclosure.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-07-06
Item 8.01
The disclosure reports completion of a partial real estate disposition—closing on two of three properties (Green Valley and Kingman) for $1.0 million in aggregate proceeds on June 30, 2026, with the third property (Chino Valley) closing deferred to August 31, 2026. While this is a sale of assets, it does not rise to the level of a material acquisition, disposition, or change of control (which would trigger ma_activity); rather, it is a discrete asset sale that affects the company's financial position and liquidity. The transaction is material to investors as it represents a significant capital event and reduction in the company's real estate holdings.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-07-06
Ms. Chao Suo has tendered her resignation as a member of the Company's board of directors and compensation committee member, effective July 31, 2026. This is a clear executive departure disclosure. The resignation of a board member and committee member is material to investors assessing the registrant's governance and leadership structure, even though the resignation is attributed to personal reasons rather than dispute.
View raw filing on EDGAR →
6-K
Financial Other
confidence 85%
filed 2026-07-06
EX-99.1
Radiopharm announces receipt of a A$5.9M R&D tax refund from the Australian Government for the 2025 financial year. This is a material financial event — a significant cash inflow that the company explicitly states "will provide important funding for continued development" of its product pipeline. While not a traditional debt issuance, equity offering, or dividend, it is a material financial event that affects the registrant's liquidity and capital position, and does not fit the specific named financial categories (debt_issuance, dividend_distribution, etc.).
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-06
EX-99.1
This press release announces completion of patient enrollment (247 patients) in a pivotal Phase 3 clinical trial for Piclidenoson in psoriasis, with interim analysis expected Q4 2026/Q1 2027 under FDA and EMA-agreed protocol. This is a material clinical development milestone for a clinical-stage biotech company, but it is not a discrete event type in the taxonomy (not earnings, M&A, litigation, or a specific financial/governance action). It represents a significant operational/strategic advancement in the company's drug development pipeline that would affect a reasonable investor's assessment of the registrant's progress toward regulatory approval and commercialization.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Keel Infrastructure Corp. appointed Ganesh Aiyer as President, effective July 6, 2026, reporting directly to CEO Ben Gagnon. Aiyer brings 25 years of experience from senior roles at Digital Realty Trust, Schneider Electric, and Dell Technologies, and will be responsible for commercial strategy and pipeline expansion. The appointment includes compensatory arrangements comprising a $500,000 base salary, bonus plan eligibility, 100,000 stock options, $1.5M in RSUs, and severance provisions.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-06
The 6-K discloses the final voting results from three shareholder meetings held on July 6, 2026: a Class A Meeting, a Class B Meeting, and an Annual General Meeting. The results include approval of significant structural changes including an increase in Class B voting rights from 35 to 100 votes per share, adoption of amended articles of association, a 1-for-400 Class A share consolidation, a par value reduction, and an authorized share capital increase. These governance and capital structure changes are material to investors and directly correspond to Item 5.07 disclosure requirements.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-06
On July 1, 2026, the Board appointed Ms. Sha, XIA as a Director of Grande Group Limited to fill the vacancy created by Mr. Ying Wo Sammy, HO's resignation on April 15, 2026. The filing discloses the appointment of a director, her employment agreement with an annual salary of HK$180,000, and her professional background. This is a clear executive appointment event material to investors assessing the company's leadership composition.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-06
Item 1.01
Ondas Inc. completed the acquisition of DZYNE Technologies, LLC (High Point UAS, LLC) on July 2, 2026, for $875 million in total consideration ($200 million cash and 85 million shares of common stock valued at $675 million). The acquisition materially expands Ondas' autonomous defense platform across persistent intelligence, aerial security, counter-UAS, and autonomous effects, with projected 2027 revenue exceeding $300 million and 80%+ revenue CAGR through 2028.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-06
EX-99.1
Immuron announced engagement of Pullan Consulting to advance partnering strategy for IMM-529, a clinical-stage CDI therapeutic with FDA IND approval. The disclosure details the company's strategic initiative to secure a development and commercialization partner, including market opportunity assessment (projected $400M base case annual revenue) and historical CDI deal benchmarks. This is a material operational/strategic milestone advancing a key asset toward commercialization, but does not fit discrete event categories like M&A (no deal executed), exec changes, or financial events—it is a business development initiative that would affect investor assessment of the company's strategy and value creation path.
View raw filing on EDGAR →